February 2020
Triple-Negative Breast Cancer: Improved Outcomes and Providing Patient-Centered Care
March 03, 2020
Article
Directions in Pharmacy
Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.
The Evolution of Oncology Biosimilars and the Potential to Improve Patient Access to Biologics
March 02, 2020
Article
Directions in Pharmacy
A session on the use of biosimilars, a topic that many pharmacists identify to be of growing importance in their practices, concluded the 2019 Directions in Oncology Pharmacy conference.
PARP Inhibitors: A Novel Approach to Treating Ovarian Cancer
March 02, 2020
Article
Directions in Pharmacy
PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.
Melanoma: Increasing Cases and Growing Treatment Possibilities
March 01, 2020
Article
Directions in Pharmacy
With cases of melanoma increasing more rapidly than those of other malignancies (especially in men), no conference on oncology pharmacy would be complete without a session covering this topic and its expansion of treatment options.
Heterogenous Disease Creates Challenges in AML; New Treatment Options Offer Solutions
March 01, 2020
Article
Directions in Pharmacy
Many people are unaware that acute myeloid leukemia (AML) is the leading cause of acute leukemia in adults.
Clinical Insights: Use of Combination Therapy for Advanced Clear-Cell Renal Cell Carcinoma
February 29, 2020
Article
Directions in Pharmacy
Approximately 73,000 NEW cases of renal cell carcinoma (RCC) are expected to be diagnosed in 2019 in the United States, with up to 70% of these cases anticipated to be clear-cell subtype.
Asembia's Summit to Launch Another Transformative Year for Specialty Pharmacy
February 28, 2020
Article
Directions in Pharmacy
Asembia's 2020 Specialty Pharmacy Summit (May 3-7 at the Wynn & Encore in Las Vegas) will bring together stakeholders from across the industry to investigate challenges and collectively generate solutions.
Patient Assistance Programs: A Lifeline for Individuals With Cancer
February 28, 2020
Article
Directions in Pharmacy
Oncologists have grown increasingly concerned that high costs create ‘financial toxicity’ and may keep patients from getting needed treatments.
Health System Specialty Pharmacy: Benefits to Oncology Prescription Turnaround Times
February 27, 2020
Article
Directions in Pharmacy
Prior authorization (PA) requirements, cost, and other factors can lead to turnaround times of up to 3 weeks, delaying the start of therapy and creating substantial anxiety for patients.
New Combination Therapies for the Treatment of Chronic Lymphocytic Leukemia
February 25, 2020
Article
Directions in Pharmacy
Patients with CLL may have genetic mutations that predict response to different treatments.
CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant Cells
February 25, 2020
Article
Directions in Pharmacy
Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.
Herceptin Hylecta for HER2-Positive Breast Cancer
February 24, 2020
Article
Directions in Pharmacy
HER2 is a membrane-bound tyrosine kinase that when amplified contributes significantly to a tumor’s ability to proliferate and survive.
Understanding the Oncology Distribution Model
February 24, 2020
Article
Directions in Pharmacy
As the growth of specialty continues at a record pace, pharmacy must keep up with new distribution trends as an oncology product’s supply chain of a product can take many paths.
Staying Ahead of the Curve
February 23, 2020
Article
Directions in Pharmacy
To stay up-to-date on the latest in oncology pharmacy, make sure to check out the slate of programming that will be offered this year through our Directions in Oncology PharmacyTM series.
Immune Checkpoint Inhibitors in Head and Neck Cancers Offer Different Treatment Approaches
February 21, 2020
Article
Directions in Pharmacy
Guidelines indicate that there are a number of treatment options for head and neck cancers.